Koiwai Hidefumi, Kamimura Mikio, Takahashi Jun, Nakamura Yukio, Kato Hiroyuki
Koiwai Orthopedic Clinic, Mikageshinden 1585-4, Komoro, 384-0091, Japan.
Center of Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic, Kotobuki 595-17, Matsumoto, 399-0021, Japan.
J Med Case Rep. 2019 Sep 13;13(1):288. doi: 10.1186/s13256-019-2219-0.
Osteoporosis is a serious disease that causes bone fragility fractures and increases mortality. Bisphosphonates are the first-line drugs for osteoporosis. However, the gains in bone mineral density by use of bisphosphonates alone are limited.
We describe the clinical outcome of a Japanese woman with osteoporosis treated with bisphosphonates after multiple spinal fractures. After 3 years of treatment with the bisphosphonate alendronate, her lumbar bone mineral density and bilateral hip bone mineral density markedly increased by 61.9% and 32.5%, respectively.
We considered that our patient's multiple fractures had caused a decrease in bone mineral density, which naturally improved with fracture healing to enhance the increase in bone mineral density with bisphosphonate treatment.
骨质疏松症是一种严重疾病，可导致脆性骨折并增加死亡率。双膦酸盐是治疗骨质疏松症的一线药物。然而，单纯使用双膦酸盐所带来的骨密度增加是有限的。
我们描述了一名日本骨质疏松症女性患者在多次脊柱骨折后接受双膦酸盐治疗的临床结果。在用双膦酸盐阿仑膦酸钠治疗3年后，她的腰椎骨密度和双侧髋部骨密度分别显著增加了61.9%和32.5%。
我们认为，患者的多次骨折导致骨密度下降，随着骨折愈合，骨密度自然改善，从而增强了双膦酸盐治疗带来的骨密度增加。
Zotero 插件